Coeptis Historical Balance Sheet

COEP Stock

USD 8.50 2.56 23.15%

Trend analysis of Coeptis Therapeutics balance sheet accounts such as Short Long Term Debt Total of 1.6 M, Total Current Liabilities of 2.3 M or Total Stockholder Equity of 4.5 M provides information on Coeptis Therapeutics' total assets, liabilities, and equity, which is the actual value of Coeptis Therapeutics to its prevalent stockholders. By breaking down trends over time using Coeptis Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Coeptis Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Coeptis Therapeutics is a good buy for the upcoming year.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Coeptis Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

To learn how to invest in Coeptis Stock, please use our How to Invest in Coeptis Therapeutics guide.

About Coeptis Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Coeptis Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Coeptis Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Coeptis Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Coeptis currently owns. An asset can also be divided into two categories, current and non-current.

Coeptis Therapeutics Balance Sheet Chart

At this time, Coeptis Therapeutics' Intangible Assets are relatively stable compared to the past year. As of 03/18/2025, Common Stock is likely to grow to 4,034, though Net Debt is likely to grow to (232.7 K).

Total Assets Short Long Term Debt Total Total Current Liabilities Accounts Payable

Total Assets

Total assets refers to the total amount of Coeptis Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Coeptis Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Coeptis Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Coeptis Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Coeptis Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Coeptis Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most accounts from Coeptis Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Coeptis Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Coeptis Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

To learn how to invest in Coeptis Stock, please use our How to Invest in Coeptis Therapeutics guide.At this time, Coeptis Therapeutics' Intangible Assets are relatively stable compared to the past year. As of 03/18/2025, Common Stock is likely to grow to 4,034, though Net Debt is likely to grow to (232.7 K).

	2021	2022	2024	2025 (projected)
Short and Long Term Debt Total	4.1M	1.7M	1.2M	1.6M
Total Assets	6.8M	7.9M	4.6M	3.8M

Short Long Term Debt Total Total Assets

Coeptis Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Net Tangible Assets	Other Assets	Property Plant Equipment	Other Current Liab	Current Deferred Revenue	Non Currrent Assets Other	Net Receivables	Property Plant And Equipment Net	Long Term Debt
Total Assets		0.75	-0.14	0.8	-0.48	-0.81	-0.64	0.98	0.99	0.98	0.52	0.8	0.68	0.87	0.78	0.23	-0.1	0.85	0.75	0.05	-0.6	0.83	0.22	0.37	-0.2	0.41
Short Long Term Debt Total	0.75		0.23	0.32	0.21	-0.53	-0.49	0.67	0.81	0.67	0.67	0.55	0.88	0.46	0.97	0.22	-0.08	0.47	0.36	0.23	-0.45	0.84	-0.22	0.53	-0.51	0.75
Total Current Liabilities	-0.14	0.23		-0.41	0.46	0.04	0.65	-0.16	-0.12	-0.16	0.54	-0.05	0.37	-0.03	0.28	0.48	-0.57	-0.33	-0.13	-0.17	0.36	0.23	-0.64	0.25	0.03	0.06
Total Stockholder Equity	0.8	0.32	-0.41		-0.69	-0.8	-0.43	0.78	0.8	0.78	0.26	0.79	0.24	0.77	0.32	0.24	-0.04	0.96	0.82	-0.09	-0.63	0.48	0.66	0.37	0.11	0.13
Net Debt	-0.48	0.21	0.46	-0.69		0.49	0.3	-0.59	-0.36	-0.59	0.17	-0.47	0.12	-0.69	0.09	-0.04	0.06	-0.59	-0.64	0.16	0.24	-0.14	-0.49	0.18	-0.36	0.48
Retained Earnings	-0.81	-0.53	0.04	-0.8	0.49		0.34	-0.79	-0.8	-0.79	-0.6	-1.0	-0.67	-0.65	-0.62	-0.33	0.1	-0.91	-0.98	-0.18	0.32	-0.83	-0.11	-0.73	-0.32	-0.02
Accounts Payable	-0.64	-0.49	0.65	-0.43	0.3	0.34		-0.64	-0.62	-0.64	-0.02	-0.36	-0.38	-0.35	-0.49	0.35	-0.48	-0.48	-0.31	-0.39	0.46	-0.45	-0.17	-0.01	0.34	-0.37
Cash	0.98	0.67	-0.16	0.78	-0.59	-0.79	-0.64		0.94	1.0	0.43	0.79	0.64	0.9	0.73	0.2	-0.11	0.82	0.77	0.05	-0.55	0.79	0.19	0.28	-0.15	0.26
Non Current Assets Total	0.99	0.81	-0.12	0.8	-0.36	-0.8	-0.62	0.94		0.94	0.56	0.79	0.7	0.82	0.8	0.25	-0.09	0.85	0.71	0.05	-0.65	0.83	0.25	0.45	-0.25	0.52
Cash And Short Term Investments	0.98	0.67	-0.16	0.78	-0.59	-0.79	-0.64	1.0	0.94		0.43	0.79	0.64	0.9	0.73	0.2	-0.11	0.82	0.77	0.05	-0.55	0.79	0.19	0.28	-0.15	0.26
Common Stock Shares Outstanding	0.52	0.67	0.54	0.26	0.17	-0.6	-0.02	0.43	0.56	0.43		0.59	0.79	0.34	0.7	0.67	-0.05	0.43	0.46	0.28	-0.04	0.79	-0.32	0.69	0.11	0.34
Other Stockholder Equity	0.8	0.55	-0.05	0.79	-0.47	-1.0	-0.36	0.79	0.79	0.79	0.59		0.68	0.63	0.63	0.32	-0.07	0.91	0.97	0.22	-0.32	0.83	0.09	0.75	0.29	0.03
Total Liab	0.68	0.88	0.37	0.24	0.12	-0.67	-0.38	0.64	0.7	0.64	0.79	0.68		0.39	0.95	0.25	-0.1	0.45	0.53	0.35	-0.13	0.96	-0.5	0.67	-0.11	0.4
Total Current Assets	0.87	0.46	-0.03	0.77	-0.69	-0.65	-0.35	0.9	0.82	0.9	0.34	0.63	0.39		0.51	0.34	-0.35	0.72	0.66	-0.27	-0.55	0.58	0.35	0.07	-0.13	0.17
Short Term Debt	0.78	0.97	0.28	0.32	0.09	-0.62	-0.49	0.73	0.8	0.73	0.7	0.63	0.95	0.51		0.25	-0.1	0.49	0.47	0.29	-0.35	0.92	-0.35	0.55	-0.37	0.58
Intangible Assets	0.23	0.22	0.48	0.24	-0.04	-0.33	0.35	0.2	0.25	0.2	0.67	0.32	0.25	0.34	0.25		0.0	0.29	0.31	0.21	-0.07	0.29	-0.03	0.35	0.11	0.03
Common Stock	-0.1	-0.08	-0.57	-0.04	0.06	0.1	-0.48	-0.11	-0.09	-0.11	-0.05	-0.07	-0.1	-0.35	-0.1	0.0		0.04	-0.07	0.82	0.02	-0.1	0.04	-0.01	0.01	0.0
Net Tangible Assets	0.85	0.47	-0.33	0.96	-0.59	-0.91	-0.48	0.82	0.85	0.82	0.43	0.91	0.45	0.72	0.49	0.29	0.04		0.91	0.11	-0.57	0.66	0.47	0.56	0.15	0.16
Other Assets	0.75	0.36	-0.13	0.82	-0.64	-0.98	-0.31	0.77	0.71	0.77	0.46	0.97	0.53	0.66	0.47	0.31	-0.07	0.91		0.17	-0.28	0.71	0.18	0.63	0.42	-0.16
Property Plant Equipment	0.05	0.23	-0.17	-0.09	0.16	-0.18	-0.39	0.05	0.05	0.05	0.28	0.22	0.35	-0.27	0.29	0.21	0.82	0.11	0.17		0.13	0.28	-0.4	0.35	0.06	-0.04
Other Current Liab	-0.6	-0.45	0.36	-0.63	0.24	0.32	0.46	-0.55	-0.65	-0.55	-0.04	-0.32	-0.13	-0.55	-0.35	-0.07	0.02	-0.57	-0.28	0.13		-0.24	-0.58	-0.07	0.52	-0.55
Current Deferred Revenue	0.83	0.84	0.23	0.48	-0.14	-0.83	-0.45	0.79	0.83	0.79	0.79	0.83	0.96	0.58	0.92	0.29	-0.1	0.66	0.71	0.28	-0.24		-0.28	0.67	0.0	0.33
Non Currrent Assets Other	0.22	-0.22	-0.64	0.66	-0.49	-0.11	-0.17	0.19	0.25	0.19	-0.32	0.09	-0.5	0.35	-0.35	-0.03	0.04	0.47	0.18	-0.4	-0.58	-0.28		-0.2	-0.06	0.11
Net Receivables	0.37	0.53	0.25	0.37	0.18	-0.73	-0.01	0.28	0.45	0.28	0.69	0.75	0.67	0.07	0.55	0.35	-0.01	0.56	0.63	0.35	-0.07	0.67	-0.2		0.28	0.19
Property Plant And Equipment Net	-0.2	-0.51	0.03	0.11	-0.36	-0.32	0.34	-0.15	-0.25	-0.15	0.11	0.29	-0.11	-0.13	-0.37	0.11	0.01	0.15	0.42	0.06	0.52	0.0	-0.06	0.28		-0.79
Long Term Debt	0.41	0.75	0.06	0.13	0.48	-0.02	-0.37	0.26	0.52	0.26	0.34	0.03	0.4	0.17	0.58	0.03	0.0	0.16	-0.16	-0.04	-0.55	0.33	0.11	0.19	-0.79

Click cells to compare fundamentals

Coeptis Therapeutics Account Relationship Matchups

Coeptis Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Current Liabilities	155.9K	5.3M	2.8M	1.8M	3.0M	2.3M
Retained Earnings	(9.3K)	(14.1M)	(27.6M)	(65.7M)	(87.4M)	(83.0M)
Accounts Payable	450.0	1.6M	134.1K	99.0K	1.4M	1.5M
Other Stockholder Equity	16.9M	29.9M	70.5M	70.9M	91.7M	96.3M
Total Current Assets	505.0	224.8K	2.2M	3.9M	1.7M	1.6M
Common Stock	25K	2.5K	3.6K	2.0K	3.5K	4.0K
Net Tangible Assets	(378.5K)	(5.1M)	2.4M	4.8M	5.5M	5.8M
Other Current Liab	732.1K	199.1K	182.0K	532.0K	556.0K	360.2K

Pair Trading with Coeptis Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Coeptis Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Coeptis Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Coeptis Stock

0.7	DMAC	DiaMedica Therapeutics	Pair Corr
0.74	VALN	Valneva SE ADR Earnings Call Today	Pair Corr

Moving against Coeptis Stock

0.87	VINC	Vincerx Pharma	Pair Corr
0.86	VKTX	Viking Therapeutics	Pair Corr
0.83	DSGN	Design Therapeutics	Pair Corr
0.78	VERA	Vera Therapeutics	Pair Corr
0.58	VANI	Vivani Medical Earnings Call This Week	Pair Corr

The ability to find closely correlated positions to Coeptis Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Coeptis Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Coeptis Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Coeptis Therapeutics to buy it.

The correlation of Coeptis Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Coeptis Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Coeptis Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Coeptis Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Coeptis Stock Analysis

When running Coeptis Therapeutics' price analysis, check to measure Coeptis Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coeptis Therapeutics is operating at the current time. Most of Coeptis Therapeutics' value examination focuses on studying past and present price action to predict the probability of Coeptis Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coeptis Therapeutics' price. Additionally, you may evaluate how the addition of Coeptis Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Coeptis Historical Balance Sheet

About Coeptis Balance Sheet Analysis

Coeptis Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Accounts Payable

Coeptis Therapeutics balance sheet Correlations

Coeptis Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Coeptis Therapeutics balance sheet Accounts

Pair Trading with Coeptis Therapeutics

Moving together with Coeptis Stock

Moving against Coeptis Stock

Additional Tools for Coeptis Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Non Current Assets Total	+ 0.99	Total Assets
Cash	+ 0.98	Total Assets
Cash And Short Term Investments	+ 0.98	Total Assets
Short Term Debt	+ 0.97	Short Long Term Debt Total
Other Assets	+ 0.97	Other Stockholder Equity

Other Stockholder Equity	- 1.0	Retained Earnings
Other Assets	- 0.98	Retained Earnings
Net Tangible Assets	- 0.91	Retained Earnings
Current Deferred Revenue	- 0.83	Retained Earnings
Retained Earnings	- 0.81	Total Assets
Non Current Assets Total	- 0.8	Retained Earnings